Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Korro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating Officer
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Korro Strengthens Leadership Team with Appointment of Shelby Walker as General Counsel
Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency
Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer
Korro Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
Korro Bio Expands Leadership Team with Key Appointments
Korro Bio to Participate in 2022 Jefferies Healthcare Conference
Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine through its Pipeline of RNA Editing Programs
Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
Korro Bio to Present at the Evercore ISI 4th Annual HealthCONx Conference and the Piper Sandler 33rd Annual Virtual Healthcare Conference
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Participate in September Investor Conferences
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at 2021 Jefferies Virtual Healthcare Conference
Korro Bio Appoints Vineet Agarwal as Chief Financial Officer
Korro Bio Strengthens Leadership Team with Appointment of Howard Stern M.D., Ph.D. as Chief Scientific Officer
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
Korro Bio to Present at J.P. Morgan Healthcare Conference
Korro Bio Appoints Ram Aiyar, Ph.D., MBA, as Chief Executive Officer
Korro Bio Appoints Omar Khwaja, M.D., Ph.D. to its Board of Directors
Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics
Korro Bio Launched to Advance Groundbreaking New Approach to Nucleic Acid Editing